ID   PD-1.3
AC   CVCL_DF55
SY   PD1.3; PD1.3.1; PD1 3.1
DR   Wikidata; Q54946766
RX   Patent=US9637546;
RX   Patent=US9896507;
RX   Patent=US10005839;
RX   PubMed=20587542;
RX   PubMed=20693422;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4122.
CC   Monoclonal antibody isotype: IgG2b.
CC   Monoclonal antibody target: UniProtKB; Q15116; Human PDCD1/PD1/CD279.
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_4032 ! P3X63Ag8.653
CA   Hybridoma
DT   Created: 13-07-16; Last updated: 21-03-23; Version: 8
//
RX   Patent=US9637546;
RA   Olive D., Serriari N.-E., Nunes J.A., Ghiotto M.;
RT   "PD-1 antibodies and PD-L1 antibodies and uses thereof.";
RL   Patent number US9637546, 02-May-2017.
//
RX   Patent=US9896507;
RA   Olive D., Gondois-Rey F., Serriari N.-E., Pastor S.;
RT   "BTLA antibodies and uses thereof.";
RL   Patent number US9896507, 20-Feb-2018.
//
RX   Patent=US10005839;
RA   Olive D., Pasero C., Gertner-Dardenne J.;
RT   "Antagonist of the BTLA/HVEM interaction for use in therapy.";
RL   Patent number US10005839, 26-Jun-2018.
//
RX   PubMed=20587542; DOI=10.1093/intimm/dxq049;
RA   Ghiotto M., Gauthier L., Serriari N.-E., Pastor S., Truneh A.,
RA   Nunes J.A., Olive D.;
RT   "PD-L1 and PD-L2 differ in their molecular mechanisms of interaction
RT   with PD-1.";
RL   Int. Immunol. 22:651-660(2010).
//
RX   PubMed=20693422; DOI=10.4049/jimmunol.0902487;
RA   Serriari N.-E., Gondois-Rey F., Guillaume Y., Remmerswaal E.B.M.,
RA   Pastor S., Messal N., Truneh A., Hirsch I., van Lier R.A.W., Olive D.;
RT   "B and T lymphocyte attenuator is highly expressed on CMV-specific T
RT   cells during infection and regulates their function.";
RL   J. Immunol. 185:3140-3148(2010).
//